本帖最后由 老马 于 2012-1-13 21:20 编辑 9 C: A; h j o" z
$ ^8 Y1 ?' l. m' @! }爱必妥和阿瓦斯丁的比较
' @3 C0 N/ }: ]7 p* I
% n! |/ b3 m# Dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg// @/ ~5 o/ z" E$ Y2 d F, ~
* B+ y! f$ F; j: P& j l9 y' t, p
6 E3 r5 p0 O' w- ~: ?http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/1 t0 d0 R7 B, e; Y1 q0 g# U
==================================================" ]1 q" h- P8 o
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% u# j% R4 E0 R8 m1 \# @/ I
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.7 ~; h+ i: O# ^1 b
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ h' F9 T3 N% H2 }+ f2 U
|